MYO-INS supplementation significantly reduced the incidence of gestational diabetes (p = 0.04) and the delivery of macrosomia fetuses (p = 0.007) in pregnant women with a family history of type 2 diabetes [26] (Table 1). The gene discussed is INS; the disease is gestational diabetes.